Concepedia

Bo Jan Noordman

BJ

Statistics

Publications

20

Citations

1.7K

H-Index

17

Active since

2013

Affiliations

Erasmus MC(Current)

Erasmus University Rotterdam

Catharina Ziekenhuis

Radboud University Nijmegen

Radboud University Medical Center

Bo Jan Noordman is an author at Erasmus MC specializing in medicine, surgery, and neoadjuvant chemoradiotherapy.

ORCID

Publications per year

2013–2025

20

Publications

20

Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study

Bo Jan Noordman, Manon C.W. Spaander, Roelf Valkema et al. · The Lancet Oncology · 2018 · 332 citations

, , +17

Effectiveness of First‐Line Treatment With Recombinant Interleukin‐1 Receptor Antagonist in Steroid‐Naive Patients With New‐Onset Systemic Juvenile Idiopathic Arthritis: Results of a Prospective Cohort Study

Sebastiaan J. Vastert, Wilco de Jager, Bo Jan Noordman et al. · Arthritis & Rheumatology · 2013 · 263 citations

, , +14

Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial

Bo Jan Noordman, Bas P. L. Wijnhoven, Sjoerd M. Lagarde et al. · BMC Cancer · 2018 · 245 citations · Full text

, , +17

Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial

Bo Jan Noordman, Mathilde G. E. Verdam, Sjoerd M. Lagarde et al. · Journal of Clinical Oncology · 2017 · 129 citations · Full text

, , +17

Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial

Berend J. van der Wilk, Ben M. Eyck, Bas P. L. Wijnhoven et al. · The Lancet Oncology · 2025 · 90 citations · Full text

, , +17

1–5 of 20